Mitochondrial Agents for Bipolar Disorder

Abstract

BackgroundBipolar disorder is a chronic and often debilitating illness. Current treatment options (both pharmaco- and psychotherapy) have shown efficacy, but for many leave a shortfall in recovery. Advances in the understanding of the pathophysiology of bipolar disorder suggest that interventions that target mitochondrial dysfunction may provide a therapeutic benefit.MethodsThis review explores the current and growing theoretical rationale as well as existing preclinical and clinical data for those therapies aiming to target the mitochondrion in bipolar disorder. A Clinicaltrials.gov and ANZCTR search was conducted for complete and ongoing trials on mitochondrial agents used in psychiatric disorders. A PubMed search was also conducted for literature published between January 1981 and July 2017. Systematic reviews, randomized controlled trials, observational studies, case series, and animal studies with an emphasis on agents affecting mitochondrial function and its role in bipolar disorder were included. The search was augmented by manually searching the references of key papers and related literature. The results were presented as a narrative review.ResultsMitochondrial agents offer new horizons in mood disorder treatment. While some negative effects have been reported, most compounds are overall well tolerated and have generally benign side-effect profiles.ConclusionsThe study of neuroinflammation, neurodegeneration, and mitochondrial function has contributed the understanding of bipolar disorder’s pathophysiology. Agents targeting these pathways could be a potential therapeutic strategy. Future directions include identification of novel candidate mitochondrial modulators as well as rigorous and well-powered clinical trials.

Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches

“…Recent evidence points to mitochondria as one of the main loci for the pathogenesis of bipolar disorder [70]. An increasing number of agents capable of enhancing antioxidant defenses or mitochondrial functioning have recently been studied for the treatment of mood disorders, which could also be worth considering as adjuvant therapy to current pharmacological treatments for NAFLD [71]. Other disorders, such as PTSD [72], psychosis [73,74], schizophrenia [75], depression [76][77][78], and autism [79], have also been linked to oxidative stress and mitochondrial dysregulation.…”

Mitochondria, Microglia, and the Immune System—How Are They Linked in Affective Disorders?

“…Further, a recent study exposed functional perturbations of apoptotic mitochondrial stress signaling induced by BID as a potential therapeutic target in rodent models of depression (134). Targeting such mechanisms of mitochondrial damage may provide novel therapeutic approaches in both, age-related disorders of the nervous system and psychiatric disorders (135–137). Systematic studies investigating the impact of genetic risk factors and environmental stress on mitochondrial functions and morphological alterations are highly warranted for a better understanding of the proposed link between the course of psychiatric disorders and mitochondrial demise.…”

eNACT: A protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first episode psychosis

“…Molecular pathology underlying psychotic disorders is far more complex, and multiple operative systems have been identified apart from dopaminergic dysregulation, including disturbed glutamatergic neurotransmission, mitochondrial dysfunction, apoptosis, reduced neurogenesis, and pro-inflammatory status of the brain. NAC has broader effects with evidence that it impacts glutamate, reduces oxidative stress and inflammation, improves mitochondrial dysfunction, decreases apoptosis, and enhances neurogenesis (81). Given evidence of the neuroprotective potential of NAC in individuals with enduring psychotic disorders, demonstrated clinical and cognitive improvements in schizophrenia, and changes in imaging markers of neuroprotection in other psychotic disorders, this study has the potential to support the development of a novel, safer and more efficacious treatment option for people with FEP.…”